Shots:
The EC has approved an expansion of the indication for Crysvita (burosumab) for the treatment of X-linked hypophosphataemia (XLH), to incl. infants from 1mos. to 1yr. of age
Approval was supported by data from P-I/II (BUR-CL207) study assessing safety, tolerability, PK & efficacy of burosumab in pts with XLH from birth to 1yr. Trial showed…
Shots:
Abdul spoke about the launch of a digital exhibition ‘Shine a light’ to raise awareness about rare diseases
Abdul also emphasized the significance of this awareness campaign for the patients who were unaware of X-linked Hypophosphataemia(XLH)
The interview provides a profound understanding of Kyowa Kirin's initiatives to help patients suffering from XLH
Smriti: Can we…

